Mesenchymal stem cells and platelet rich plasma in the treatment of premature ovarian insufficiency: a scoping review.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Premature ovarian Insufficiency (POI) is characterized by amenorrhea, hypergonadotropic hypogonadism, estrogen deficiency, and reduced follicle counts leading to infertility under the age of 40. It occurs in 1 to 3% of women. Several therapeutic strategies have been explored in clinic for POI. Platelet Rich Plasma (PRP) a blood product applied in regenerative medicine, which is based on the releasing of the growth factors present in platelet. Mesenchymal Stem Cells derived from Bone marrow, adipose tissue or cord blood tissue are undifferentiated cells with a potential for self-renewal and differentiation into multiple mature cell type. Mesenchymal stem cells secretome can stimulate cellular process and activate multipotent stem cells to generate new younger tissue and blood vessels relevant to ovarian rejuvenation and endometrial regeneration. This review provides a critical analysis on novel treatments that have not achieve routine clinical practice status yet but have recently emerged as promising potential therapy.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.